drugset / Trial / NCT03097029

Use of Pancreatic Enzymes in Short Bowel Syndrome

NCT03097029

NaSingle-groupOpen-labelTreatment

Summary

Patients with short bowel syndrome have a high mortality rate that is mainly attributed to complications from central lines and long-term intravenous (IV) nutrition. There are few medical therapies to date that improve gut absorption in patients with short bowel syndrome. The primary objective of this study is to evaluate if absorption from the GI tract improves in subjects with short bowel syndrome following therapy with pancreatic enzymes.

Timeline

Start
2017-03-24
Primary completion
2019-02-01
Completion
2019-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pancrelipase Protein / enzyme biologic

Indications